Medicare Enrolled
Dr. Mikell Jarratt, M.D.
Pulmonary Disease · Gastonia, NC
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Jarratt from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Jarratt?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Jarratt
Dr. Mikell Jarratt is a pulmonary disease specialist in Gastonia, NC, with 20 years of NPI registration. Based on federal Medicare data, Dr. Jarratt performed 2,042 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Jarratt received a total of $45,593 from 67 pharmaceutical and/or device companies across 882 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Jarratt is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 14% volume in NC
$45,593 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗2,042
Medicare services
Top 14% in NC for pulmonary disease
Not available
Unique patients (not deduplicated)
$59
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
671 | $61 | $177 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
441 | $62 | $176 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
301 | $58 | $176 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
113 | $129 | $495 |
| Chest X-ray, 2 views An X-ray imaging test of the chest that captures two different angles to visualize the lungs, heart, and chest wall. |
101 | $23 | $95 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
96 | $12 | $72 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
74 | $26 | $107 |
| Lung volume test using gas dilution or washout A test that measures the amount of air in your lungs by using a gas dilution or washout method. |
73 | $22 | $86 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
72 | $88 | $248 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
60 | $38 | $98 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
22 | $122 | $385 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
18 | $76 | $218 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
Industry Payment Transparency
Open Payments through 2024 ↗$45,593
Total received (2018-2024)
Avg $6,513/year across 7 years
Top 8% in NC for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
67
Companies
882
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,164
2023
$2,261
2022
$2,267
2021
$9,233
2020
$11,733
2019
$15,776
2018
$2,158
Payments by company (2024)
GlaxoSmithKline, LLC.
$302
AstraZeneca Pharmaceuticals LP
$193
GENZYME CORPORATION
$162
Novo Nordisk Inc
$155
Bayer Healthcare Pharmaceuticals Inc.
$136
Actelion Pharmaceuticals US, Inc.
$133
Boehringer Ingelheim Pharmaceuticals, Inc.
$130
Lilly USA, LLC
$108
Mylan Specialty L.P.
$97
Regeneron Healthcare Solutions, Inc.
$96
ABBVIE INC.
$83
Avadel CNS Pharmaceuticals, LLC
$79
Insmed, Inc.
$67
Electromed, Inc.
$66
Mallinckrodt Hospital Products Inc.
$56
PFIZER INC.
$48
Radius Health, Inc.
$46
Janssen Pharmaceuticals, Inc
$36
Amgen Inc.
$30
Merck Sharp & Dohme LLC
$28
Inspire Medical Systems, Inc.
$26
SHIELD THERAPEUTICS INC
$23
Novartis Pharmaceuticals Corporation
$21
Verity Pharmaceuticals Inc.
$17
Dexcom, Inc.
$15
MEDICOMP INC
$13
Top 3 companies account for 30.3% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$30,959
AstraZeneca Pharmaceuticals LP
$1,749
ViiV Healthcare Company
$1,600
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,304
Merck Sharp & Dohme Corporation
$874
Novo Nordisk Inc
$842
Janssen Pharmaceuticals, Inc
$696
Mylan Specialty L.P.
$605
Lilly USA, LLC
$587
Regeneron Healthcare Solutions, Inc.
$512
Insmed, Inc.
$460
Actelion Pharmaceuticals US, Inc.
$427
Amgen Inc.
$406
GENZYME CORPORATION
$401
Radius Health, Inc.
$287
ABBVIE INC.
$277
Sunovion Pharmaceuticals Inc.
$274
Bayer Healthcare Pharmaceuticals Inc.
$265
Mallinckrodt Hospital Products Inc.
$193
Electromed, Inc.
$190
Philips Electronics North America Corporation
$180
Circassia Pharmaceuticals Inc
$159
PFIZER INC.
$145
Grifols USA, LLC
$135
Bayer HealthCare Pharmaceuticals Inc.
$133
Teva Pharmaceuticals USA, Inc.
$126
Harmony Biosciences LLC
$122
Genentech USA, Inc.
$111
Paratek Pharmaceuticals, Inc.
$90
Novartis Pharmaceuticals Corporation
$88
Merck Sharp & Dohme LLC
$87
Inogen, Inc.
$83
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$83
Avadel CNS Pharmaceuticals, LLC
$79
SANOFI-AVENTIS U.S. LLC
$78
Amarin Pharma Inc.
$74
AbbVie Inc.
$62
Shield Therapeutics Inc
$62
Nabriva Therapeutics, plc
$62
Takeda Pharmaceuticals U.S.A., Inc.
$57
Eisai Inc.
$51
Abbott Laboratories
$47
Masimo Corporation
$46
Biohaven Pharmaceutical Holding Company Ltd.
$42
Inspire Medical Systems, Inc.
$41
Resmed Corp
$39
CeQur Corporation
$37
Pulmonx Corporation
$34
Biohaven Pharmaceuticals, Inc.
$34
JAZZ PHARMACEUTICALS INC.
$32
Baxter Healthcare
$29
SHIELD THERAPEUTICS INC
$23
E.R. Squibb & Sons, L.L.C.
$21
Astellas Pharma US Inc
$17
Verity Pharmaceuticals Inc.
$17
Mallinckrodt Enterprises LLC
$17
Shire North American Group Inc
$15
Dexcom, Inc.
$15
Kowa Pharmaceuticals America, Inc.
$14
Fisher & Paykel Healthcare Inc
$13
Mallinckrodt LLC
$13
OptiNose US, Inc.
$13
ADVANCED RESPIRATORY, INC
$13
MEDICOMP INC
$13
Daiichi Sankyo Inc.
$12
Advanced Respiratory, Inc
$12
Tactile Systems Technology Inc
$11
Top 3 companies account for 75.2% of all-time payments
Associated products mentioned in payments ›
(8746) Vent Connectivity · (8874) inCourage · (8876) Vest Therapy Und · ACCRUFER · ACTHAR · AIR 11 · AIRSUPRA · ANORO · ANORO ELLIPTA · AREXVY · Aimovig · AirDuo Digihaler · Arikayce · BASAGLAR · BEVESPI AEROSPHERE · BEXSERO · BREO · BREO ELLIPTA · BREZTRI · BREZTRI AEROSPHERE · CAPVAXIVE · CHANTIX · CHARTIS CATHETER · CINQAIR · CeQur Simplicity · DUAKLIR PRESSAIR · DUPIXENT · Dayvigo · Dexcom G6 Transmitter · ELIQUIS · EMGALITY · ENTRESTO · EVENITY · Esbriet · FARXIGA · FASENRA · FISHER & PAYKEL HEALTHCARE · FORTEO · FREESTYLE LIBRE 3 · Flexitouch Plus · FreeStyle Libre 2 · GLASSIA · Hillrom - Life 2000 Ventilation System · IMFINZI · INJECTAFER · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · INSPIRE · INVOKANA · InogenOne · JANUVIA · JARDIANCE · Kerendia · LONHALA MAGNAIR · LUMRYZ · Levemir · Livalo · MK-7264 · MOUNJARO · NUCALA · NURTEC ODT · NUZYRA · OFEV · OPSUMIT · Otezla · Ozempic · PNEUMOVAX 23 · PREVNAR 20 · Perforomist · Prolastin-C Liquid · Prolia · Pulmonx Endobronchial Valve EBV · QGE031 · QULIPTA · QVAR · Repatha · Rybelsus · SEEBRI · SET and rainbow SET · SHINGRIX · SMARTVEST · SOLIQUA 100/33 · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · Saxenda · TELEPATCH CARDIAC MONITOR · TEZSPIRE · TOUJEO · TRADJENTA · TRELEGY ELLIPTA · TRINTELLIX · TRULICITY · TUDORZA PRESSAIR · The Vest System Model 105 Home Care · The VitalCough System · Tlando · Tresiba · Trilogy 100 · Tymlos · UBRELVY · UPTRAVI · UTIBRON · Utibron · VESICARE · VRAYLAR · Vascepa · Victoza · WAKIX · Wakix · Wegovy · XARELTO · XIFAXAN · XOLAIR · XYWAV · Xenleta · Xhance · Xolair · YUPELRI · Yupelri · ZERBAXA · inCourage
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Pulmonary diseases in nearby ZIP areas
28
County median income
$65,472
Nearest hospital to ZIP centroid (approximate)
CAROMONT REGIONAL MEDICAL CENTER
5.1 mi
5.1 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Jarratt is a clinical cardiology specialist, with above-average Medicare volume (top 14% in NC), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Jarratt experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Dr. Jarratt performed 671 hospital follow-up visit, moderate complexity services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Jarratt receive payments from pharmaceutical companies?
Yes. Dr. Jarratt received a total of $45,593 from 67 companies across 882 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Jarratt's costs compare to other pulmonary diseases in Gastonia?
Dr. Jarratt's average Medicare payment per service is $59. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Jarratt) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Gastonia
Browse pulmonary diseases in Gastonia ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in NC
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in NC
Which NC pulmonary diseases receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
ViiV Healthcare Company Payments to Doctors
See all physicians who received payments from ViiV Healthcare Company.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology